KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Liabilities and Shareholders Equity (2016 - 2025)

Charles River Laboratories International has reported Liabilities and Shareholders Equity over the past 17 years, most recently at $7.1 billion for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $7.1 billion for Q4 2025, down 5.22% from a year ago — trailing twelve months through Dec 2025 was $29.8 billion (down 5.82% YoY), and the annual figure for FY2025 was $7.1 billion, down 5.22%.
  • Liabilities and Shareholders Equity for Q4 2025 was $7.1 billion at Charles River Laboratories International, down from $7.5 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CRL hit a ceiling of $8.2 billion in Q4 2023 and a floor of $5.8 billion in Q1 2021.
  • Median Liabilities and Shareholders Equity over the past 5 years was $7.5 billion (2022), compared with a mean of $7.4 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: rose 28.23% in 2021 and later decreased 8.13% in 2024.
  • Charles River Laboratories International's Liabilities and Shareholders Equity stood at $7.0 billion in 2021, then increased by 8.24% to $7.6 billion in 2022, then rose by 7.79% to $8.2 billion in 2023, then fell by 8.13% to $7.5 billion in 2024, then dropped by 5.22% to $7.1 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $7.1 billion (Q4 2025), $7.5 billion (Q3 2025), and $7.6 billion (Q2 2025) per Business Quant data.